The stock of Voyager Therapeutics Inc (VYGR) has seen a 1.70% increase in the past week, with a -3.39% drop in the past month, and a -20.35% decrease in the past quarter. The volatility ratio for the week is 3.59%, and the volatility levels for the past 30 days are at 4.03% for VYGR. The simple moving average for the last 20 days is -1.87% for VYGR stock, with a simple moving average of -25.29% for the last 200 days.
Is It Worth Investing in Voyager Therapeutics Inc (NASDAQ: VYGR) Right Now?
The price-to-earnings ratio for Voyager Therapeutics Inc (NASDAQ: VYGR) is above average at 20.91x. The 36-month beta value for VYGR is also noteworthy at 0.91. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VYGR is 45.17M, and at present, short sellers hold a 9.40% of that float. The average trading volume of VYGR on October 04, 2024 was 420.85K shares.
VYGR) stock’s latest price update
The stock of Voyager Therapeutics Inc (NASDAQ: VYGR) has increased by 2.92 when compared to last closing price of 5.82. Despite this, the company has experienced a 1.70% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-29 that LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on August 28, 2024, and the restricted stock unit award is scheduled to become effective on October 1, 2024.
Analysts’ Opinion of VYGR
Many brokerage firms have already submitted their reports for VYGR stocks, with Guggenheim repeating the rating for VYGR by listing it as a “Buy.” The predicted price for VYGR in the upcoming period, according to Guggenheim is $22 based on the research report published on March 26, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VYGR reach a price target of $30. The rating they have provided for VYGR stocks is “Buy” according to the report published on March 19th, 2024.
Citigroup gave a rating of “Buy” to VYGR, setting the target price at $16 in the report published on March 07th of the current year.
VYGR Trading at -12.81% from the 50-Day Moving Average
After a stumble in the market that brought VYGR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.89% of loss for the given period.
Volatility was left at 4.03%, however, over the last 30 days, the volatility rate increased by 3.59%, as shares sank -5.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.70% lower at present.
During the last 5 trading sessions, VYGR rose by +1.70%, which changed the moving average for the period of 200-days by -24.94% in comparison to the 20-day moving average, which settled at $6.09. In addition, Voyager Therapeutics Inc saw -29.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYGR starting from Fahey Sandell Jacquelyn, who sale 5,999 shares at the price of $5.82 back on Oct 02 ’24. After this action, Fahey Sandell Jacquelyn now owns 86,001 shares of Voyager Therapeutics Inc, valued at $34,914 using the latest closing price.
Fahey Sandell Jacquelyn, the Officer of Voyager Therapeutics Inc, proposed sale 5,999 shares at $5.82 during a trade that took place back on Oct 02 ’24, which means that Fahey Sandell Jacquelyn is holding shares at $34,920 based on the most recent closing price.
Stock Fundamentals for VYGR
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.97 for the gross margin
The net margin for Voyager Therapeutics Inc stands at 0.06. The total capital return value is set at -0.02. Equity return is now at value 3.38, with 2.40 for asset returns.
Based on Voyager Therapeutics Inc (VYGR), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.42.
Currently, EBITDA for the company is 126.45 million with net debt to EBITDA at 16.36. When we switch over and look at the enterprise to sales, we see a ratio of 2.07. The receivables turnover for the company is 44.22for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.51.
Conclusion
In summary, Voyager Therapeutics Inc (VYGR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
